BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?

Last week, Bristol Myers (BMY) reported better-than-expected results for the fourth quarter. Adjusted earnings per share (EPS) of $1.67 beat the Zacks Consensus Estimate of$1.46.  In the year-ago quarter, BMY posted an adjusted EPS of $1.70.Total revenues of$12.3 billion surpassed the Zacks Consensus Estimate of $11.6 billion. The top line also increased 8% from the year-ago period’s level, primarily driven by the Growth portfolio and an increase in Eliquis sales.However, the outlook for 2025 was a dampen ...